Skip to content
Catalyst

lycopeneWhat was measured

Measured, with no finding

646 endpoints

Show what was measuredHide what was measured
  • baseline serum β-carotene, cardiovascular death vs alive

    decreases, p = 0.025

    Females | 0.969 | 0.759 (0.025) | 0.864 (0.461) | 0.679 (0.033)

    PMID 16837766 · one of two readings recorded this

  • baseline serum α-carotene, heart disease death vs alive

    decreases, p = 0.034

    α-carotene (μmol/L) | Males | 0.106 | 0.090 (0.076) | 0.081 (0.034) | 0.095 (0.391)

    PMID 16837766 · one of two readings recorded this

  • baseline serum β-carotene, stroke death vs alive

    decreases, p = 0.033

    Females | 0.969 | 0.759 (0.025) | 0.864 (0.461) | 0.679 (0.033)

    PMID 16837766 · one of two readings recorded this

  • baseline serum lycopene, cardiovascular death vs alive

    no effect, p = 0.304

    Females | 0.371 | 0.327 (0.304) | 0.248 (0.017) | 0.424 (0.539)

    PMID 16837766 · one of two readings recorded this

  • baseline serum lycopene, cardiovascular death vs alive

    no effect, p = 0.142

    Lycopene (μmol/L) | Males | 0.258 | 0.221 (0.142) | 0.237 (0.607) | 0.194 (0.056)

    PMID 16837766 · one of two readings recorded this

  • baseline serum lycopene, heart disease death vs alive

    decreases, p = 0.017

    Females | 0.371 | 0.327 (0.304) | 0.248 (0.017) | 0.424 (0.539)

    PMID 16837766 · one of two readings recorded this

  • baseline serum lycopene, heart disease death vs alive

    no effect, p = 0.607

    Lycopene (μmol/L) | Males | 0.258 | 0.221 (0.142) | 0.237 (0.607) | 0.194 (0.056)

    PMID 16837766 · one of two readings recorded this

  • baseline serum lycopene, stroke death vs alive

    no effect, p = 0.539

    Females | 0.371 | 0.327 (0.304) | 0.248 (0.017) | 0.424 (0.539)

    PMID 16837766 · one of two readings recorded this

  • baseline serum lycopene, stroke death vs alive

    no effect, p = 0.056

    Lycopene (μmol/L) | Males | 0.258 | 0.221 (0.142) | 0.237 (0.607) | 0.194 (0.056)

    PMID 16837766 · one of two readings recorded this

  • baseline serum total carotene, cardiovascular death vs alive

    no effect, p = 0.057

    Females | 1.587 | 1.321 (0.057) | 1.343 (0.214) | 1.296 (0.172)

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality by baseline serum lycopene (HPLC, log-transformed), Cox model 2 adjusted for sex, age, smoking, alcohol, BMI, systolic blood pressure, cholesterol, triglyceride and ALT

    Not recorded as a finding: a direction is stated and the estimate does not support it

    Using model 2, the hazard ratios for cardiovascular disease mortality also showed significantly low trends for serum values of α-carotene, β-carotene, and total carotene, and marginally significantly low trends for those of lycopene.

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality, Cox hazard ratio per log serum lycopene (HPLC), 3,061 Hokkaido residents, 11.9 years

    model 2 (fully adjusted) gave only a marginally significant low trend for lycopene; lycopene is named only inside a list of carotenoids and the two models disagree on significance

    Not recorded as a finding: another reason, stated per paper

    Using model 2, the hazard ratios for cardiovascular disease mortality also showed significantly low trends for serum values of α-carotene, β-carotene, and total carotene, and marginally significantly low trends for those of lycopene.

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality

    decreases

    Cardiovascular disease | α-carotene | 3,059 | 80 | 0.52 (0.37- 0.74) | 0.000 | 0.55 (0.38- 0.79) | 0.001

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality

    decreases, p = 0.001

    Cardiovascular disease | α-carotene | 3,059 | 80 | 0.52 (0.37- 0.74) | 0.000 | 0.55 (0.38- 0.79) | 0.001

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality

    decreases, p = 0.032

    Lycopene | 3,059 | 80 | 0.73 (0.55-0.97) | 0.032 | 0.77 (0.57-1.04) | 0.088

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality

    no effect, p = 0.088

    Lycopene | 3,059 | 80 | 0.73 (0.55-0.97) | 0.032 | 0.77 (0.57-1.04) | 0.088

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality

    decreases, p = 0.001

    Total carotene | 3,059 | 80 | 0.54 (0.38-0.77) | 0.001 | 0.57 (0.40-0.83) | 0.003

    PMID 16837766 · one of two readings recorded this

  • cardiovascular disease mortality

    decreases, p = 0.003

    Total carotene | 3,059 | 80 | 0.54 (0.38-0.77) | 0.001 | 0.57 (0.40-0.83) | 0.003

    PMID 16837766 · one of two readings recorded this

  • heart disease mortality

    decreases, p = 0.002

    Heart disease | α-carotene | 3,059 | 40 | 0.45 (0.27-0.73) | 0.002 | 0.51 (0.30-0.86) | 0.012

    PMID 16837766 · one of two readings recorded this

  • heart disease mortality

    decreases, p = 0.012

    Heart disease | α-carotene | 3,059 | 40 | 0.45 (0.27-0.73) | 0.002 | 0.51 (0.30-0.86) | 0.012

    PMID 16837766 · one of two readings recorded this

  • heart disease mortality

    no effect, p = 0.069

    Lycopene | 3,059 | 40 | 0.68 (0.45-1.03) | 0.069 | 0.74 (0.48-1.13) | 0.163

    PMID 16837766 · one of two readings recorded this

  • heart disease mortality

    no effect, p = 0.163

    Lycopene | 3,059 | 40 | 0.68 (0.45-1.03) | 0.069 | 0.74 (0.48-1.13) | 0.163

    PMID 16837766 · one of two readings recorded this

  • heart disease mortality

    decreases, p = 0.049

    Total carotene | 3,059 | 40 | 0.60 (0.37-0.99) | 0.049 | 0.72 (0.41-1.23) | 0.228

    PMID 16837766 · one of two readings recorded this

  • heart disease mortality

    no effect, p = 0.228

    Total carotene | 3,059 | 40 | 0.60 (0.37-0.99) | 0.049 | 0.72 (0.41-1.23) | 0.228

    PMID 16837766 · one of two readings recorded this

  • stroke mortality

    decreases, p = 0.027

    Stroke | α-carotene | 3,059 | 37 | 0.56 (0.34-0.94) | 0.027 | 0.52 (0.31-0.88) | 0.016

    PMID 16837766 · one of two readings recorded this

  • stroke mortality

    decreases, p = 0.016

    Stroke | α-carotene | 3,059 | 37 | 0.56 (0.34-0.94) | 0.027 | 0.52 (0.31-0.88) | 0.016

    PMID 16837766 · one of two readings recorded this

  • stroke mortality

    no effect, p = 0.21

    Lycopene | 3,059 | 37 | 0.76 (0.50-1.17) | 0.210 | 0.78 (0.51-1.19) | 0.253

    PMID 16837766 · one of two readings recorded this

  • stroke mortality

    no effect, p = 0.253

    Lycopene | 3,059 | 37 | 0.76 (0.50-1.17) | 0.210 | 0.78 (0.51-1.19) | 0.253

    PMID 16837766 · one of two readings recorded this

  • stroke mortality

    decreases, p = 0.005

    Total carotene | 3,059 | 37 | 0.48 (0.29-0.80) | 0.005 | 0.45 (0.28-0.76) | 0.003

    PMID 16837766 · one of two readings recorded this

  • stroke mortality

    decreases, p = 0.003

    Total carotene | 3,059 | 37 | 0.48 (0.29-0.80) | 0.005 | 0.45 (0.28-0.76) | 0.003

    PMID 16837766 · one of two readings recorded this

  • diagnosed uterine leiomyoma

    no effect

    Total lycopene intake was not associated with diagnosed UL risk

    PMID 17981250 · one of two readings recorded this

  • diagnosed uterine leiomyoma

    increases, p = 0.003

    for highest vs lowest quintile, relative risk = 1.36, 95% confidence interval 1.05 to 1.76; P(trend) = .003

    PMID 17981250 · one of two readings recorded this

  • DNA damage by comet assay

    decreases, p = 0.007

    ANOVA revealed a significant decrease in DNA damage by the comet assay (p = 0.007)

    PMID 18689558 · one of two readings recorded this

  • glucose, lipid profile and other biomarkers of lipid peroxidation

    no effect

    No significant inter- or intra-group differences were noted for glucose, lipid profile, or other biomarkers of lipid peroxidation at any dose/time point

    PMID 18689558 · one of two readings recorded this

  • lymphocyte DNA damage by comet assay and urinary 8-hydroxydeoxyguanosine (8-OHdG) after 8 weeks of purified lycopene at 0, 6.5, 15 or 30 mg/day

    decreases, p = 0.007

    Not recorded as a finding: this platform holds no node for the endpoint

    ANOVA revealed a significant decrease in DNA damage by the comet assay (p = 0.007), and a significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline (p = 0.0002), with 30 mg lycopene/day.

    PMID 18689558 · one of two readings recorded this

  • plasma lycopene

    increases, p = 0.05

    Independent of the dose, plasma lycopene levels significantly increased in all lycopene supplemented groups versus placebo (p < 0.05)

    PMID 18689558 · one of two readings recorded this

  • urinary 8-hydroxy deoxoguanosine (8-OHdG)

    decreases, p = 0.0002

    a significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline (p = 0.0002), with 30 mg lycopene/day

    PMID 18689558 · one of two readings recorded this

  • urinary 8-hydroxy deoxyguanosine (8-OHdG) and lymphocyte DNA damage by comet assay after 8 weeks of purified lycopene at 0, 6.5, 15 or 30 mg/day

    decreases, significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline, with 30 mg lycopene/day, p = 0.0002

    Not recorded as a finding: this platform holds no node for the endpoint

    ANOVA revealed a significant decrease in DNA damage by the comet assay (p = 0.007), and a significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline (p = 0.0002), with 30 mg lycopene/day.

    PMID 18689558 · one of two readings recorded this

  • hip fracture

    decreases, p = 0.01

    Subjects with higher lycopene intake had lower risk of hip fracture (p =0.01)

    PMID 19138129 · one of two readings recorded this

  • hip fracture

    no effect, p = 0.1

    A weak protective trend was observed for total beta-carotene for hip fracture alone, but associations did not reach statistical significance (p = 0.10)

    PMID 19138129 · one of two readings recorded this

  • hip fracture

    decreases, p = 0.02

    Subjects in the highest tertile of total carotenoid intake had lower risk of hip fracture (p = 0.02)

    PMID 19138129 · one of two readings recorded this

  • nonvertebral osteoporotic fracture

    decreases, p = 0.02

    Subjects with higher lycopene intake had lower risk of hip fracture (p =0.01) and nonvertebral fracture (p = 0.02)

    PMID 19138129 · one of two readings recorded this

  • acceptability of treatment form (chocolate vs capsule)

    modulates, p = 0.0001

    a marked difference in acceptability between the two treatment forms (chocolate or capsule) was revealed (p < 0.0001)

    PMID 19583878 · one of two readings recorded this

  • blood pressure change over time

    no effect

    Blood pressure changes over time within groups and between groups were not significant and independent of treatment

    PMID 19583878 · one of two readings recorded this

  • blood pressure (median, 4-weekly) in prehypertensive adults given a tomato extract capsule with 15 mg lycopene per day vs placebo

    no effect, Blood pressure changes over time within groups and between groups were not significant

    Not recorded as a finding: the supporting sentence never names the compound

    Blood pressure changes over time within groups and between groups were not significant and independent of treatment.

    PMID 19583878 · one of two readings recorded this

  • median blood pressure (SBP/DBP not separately named) over 12 weeks, tomato extract capsule with 15 mg lycopene vs placebo capsule

    no effect

    Not recorded as a finding: the supporting sentence never names the compound

    Blood pressure changes over time within groups and between groups were not significant and independent of treatment.

    PMID 19583878 · one of two readings recorded this

  • weight and other characteristics

    no effect

    Weight and other characteristics did not change significantly during the trial

    PMID 19583878 · one of two readings recorded this

  • prostate cancer risk, Gleason 2 to 6, per 10 μg/dL increase in serum lycopene

    no effect

    The odds ratios for a linear increase in lycopene (per 10 μg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively

    PMID 21335507 · one of two readings recorded this

  • prostate cancer risk, Gleason 7 to 10, per 10 μg/dL increase in serum lycopene

    no effect

    The odds ratios for a linear increase in lycopene (per 10 μg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively

    PMID 21335507 · one of two readings recorded this

  • prostate cancer risk, Gleason 8 to 10, per 10 μg/dL increase in serum lycopene

    no effect

    The odds ratios for a linear increase in lycopene (per 10 μg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively

    PMID 21335507 · one of two readings recorded this

  • risk of cancer diagnosed following elevated PSA or abnormal DRE, per 10 μg/dL increase in lycopene

    decreases

    In the placebo arm, a 10 μg/dL increase in lycopene was associated with a 7% (95% CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE

    PMID 21335507 · one of two readings recorded this

  • risk of cancer diagnosed without a biopsy prompt, per 10 μg/dL increase in lycopene

    increases

    a 10 μg/dL increase in lycopene was also associated with an 8% (95% CI: 1-16) increased risk of cancer diagnosed without a biopsy prompt

    PMID 21335507 · one of two readings recorded this

  • plasma lycopene concentration

    increases, mean 0.74 to 1.43 umol/L in the lycopene group

    Not recorded as a finding: no outcome node for plasma lycopene concentration

    For the men receiving lycopene, the mean lycopene concentration increased from 0.74 ± 0.39 to 1.43 ± 0.61 μmol/L in plasma (P < 0.0001) and from 0.45 ± 0.53 to 0.59 ± 0.47 pmol/mg in prostate tissue (P = 0.005).

    PMID 21430075 · one of two readings recorded this

  • plasma lycopene concentration

    increases, p = 0.0001

    For the men receiving lycopene, the mean lycopene concentration increased from 0.74 ± 0.39 to 1.43 ± 0.61 μmol/L in plasma (P < 0.0001)

    PMID 21430075 · one of two readings recorded this

  • plasma malondialdehyde (lipid peroxidation product) after 30 mg/d lycopene as tomato oleoresin vs placebo for 21 days

    no effect, No significant changes in the lipid peroxidation product malondialdehyde in plasma

    Not recorded as a finding: the paper never states the instrument the node requires

    No significant changes in the DNA oxidation product 8-oxo-deoxyguanosine and the lipid peroxidation product malondialdehyde were observed in prostate tissue and plasma, respectively, as a result of lycopene administration.

    PMID 21430075 · one of two readings recorded this

  • prostate tissue 8-oxo-deoxyguanosine (DNA oxidation) and plasma malondialdehyde (lipid peroxidation)

    no effect

    No significant changes in the DNA oxidation product 8-oxo-deoxyguanosine and the lipid peroxidation product malondialdehyde were observed in prostate tissue and plasma, respectively, as a result of lycopene administration

    PMID 21430075 · one of two readings recorded this

  • prostate tissue lycopene concentration

    increases, p = 0.005

    and from 0.45 ± 0.53 to 0.59 ± 0.47 pmol/mg in prostate tissue (P = 0.005)

    PMID 21430075 · one of two readings recorded this

  • androgen and estrogen metabolism pathway modulation, higher vs lower fish consumers

    modulates, p = 0.029

    modulation of androgen and estrogen metabolism in men who routinely consumed more fish (p = 0.029) and tomato (p = 0.008) compared to men who ate less

    PMID 21912659 · one of two readings recorded this

  • androgen and estrogen metabolism pathway modulation, higher vs lower tomato consumers

    modulates, p = 0.008

    modulation of androgen and estrogen metabolism in men who routinely consumed more fish (p = 0.029) and tomato (p = 0.008) compared to men who ate less

    PMID 21912659 · one of two readings recorded this

  • arachidonic acid metabolism pathway modulation (prostate gene expression)

    modulates, p = 0.01

    modulation of arachidonic acid metabolism (p = 0.01) was observed after 3 months of fish oil supplementation compared with the placebo group

    PMID 21912659 · one of two readings recorded this

  • gene expression in morphologically normal prostate tissue by cDNA microarray, differential gene expression and pathway analysis after 3 months of lycopene vs placebo

    no effect, no significant individual genes associated with supplementation of lycopene

    Not recorded as a finding: this platform holds no node for the endpoint

    We did not detect significant individual genes associated with dietary intake and supplementation of lycopene and fish oil.

    PMID 21912659 · one of two readings recorded this

  • gene expression in morphologically normal prostate tissue, cDNA microarray, individual genes and pathway analysis after 3 months of lycopene vs placebo

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    We did not detect significant individual genes associated with dietary intake and supplementation of lycopene and fish oil.

    PMID 21912659 · one of two readings recorded this

  • individual differentially expressed genes

    no effect

    Global gene expression analysis revealed no significant individual genes that were associated with high intake of fish or tomato at baseline or after 3 months of supplementation with lycopene or fish oil

    PMID 21912659 · one of two readings recorded this

  • Nrf2-mediated oxidative stress response pathway modulation (prostate gene expression)

    modulates, p = 0.01

    modulation of nuclear factor (erythroid derived-2) factor 2 or Nrf2-mediated oxidative stress response for either supplement versus placebo (fish oil: p = 0.01, lycopene: p = 0.001)

    PMID 21912659 · one of two readings recorded this

  • Nrf2-mediated oxidative stress response pathway modulation (prostate gene expression)

    modulates, p = 0.001

    modulation of nuclear factor (erythroid derived-2) factor 2 or Nrf2-mediated oxidative stress response for either supplement versus placebo (fish oil: p = 0.01, lycopene: p = 0.001)

    PMID 21912659 · one of two readings recorded this

  • circulating lycopene level, pooled mean difference

    no effect, MD 0.39 ug/mL (95% CI -0.19, 0.98)

    Not recorded as a finding: Manipulation check on the compound's own level; no outcome node for circulating lycopene

    The level of lycopene was also not statistically different in men randomised to receive lycopene and the comparison group (MD 0.39 µg/mL (micrograms/millilitre), 95% CI -0.19, 0.98).

    PMID 22071840 · one of two readings recorded this

  • incidence of prostate cancer (single study)

    unclear

    Only one study reported incidence of prostate cancer (10% in the lycopene group versus 30% in control group)

    PMID 22071840 · one of two readings recorded this

  • lycopene level

    no effect

    The level of lycopene was also not statistically different in men randomised to receive lycopene and the comparison group (MD 0.39 µg/mL (micrograms/millilitre), 95% CI -0.19, 0.98)

    PMID 22071840 · one of two readings recorded this

  • prostate cancer incidence, single study only

    10% in the lycopene group versus 30% in control

    Not recorded as a finding: No pooled estimate; one trial's raw proportions with no test statistic

    Only one study reported incidence of prostate cancer (10% in the lycopene group versus 30% in control group).

    PMID 22071840 · one of two readings recorded this

  • prostate cancer incidence, single trial, percentage of men with prostate cancer

    10% in the lycopene group versus 30% in control group

    Not recorded as a finding: Only one study reported it, so nothing is pooled and the sentence gives no direction word or test

    Only one study reported incidence of prostate cancer (10% in the lycopene group versus 30% in control group).

    PMID 22071840 · one of two readings recorded this

  • PSA level

    no effect

    Meta-analysis indicated no statistical difference in PSA levels between men randomised to receive lycopene and the comparison group (MD (mean difference) -0.34, 95% CI (confidence interval) -2.01, 1.32)

    PMID 22071840 · one of two readings recorded this

  • cardiac event-free survival (cardiac death or hospitalisation) at 1 year, Cox proportional hazards, by median split of dietary lycopene from 4-day food diaries

    increases, higher lycopene intake associated with longer cardiac event-free survival, p = 0.003

    Not recorded as a finding: this platform holds no node for the endpoint

    Higher lycopene intake was associated with longer cardiac event-free survival compared with lower lycopene intake (p = 0.003).

    PMID 23076979 · one of two readings recorded this

  • cardiac event-free survival (death or hospitalisation) over 1 year, Cox proportional hazards, by median split of dietary lycopene from 4-day food diaries in heart failure patients

    increases, higher lycopene intake associated with longer cardiac event-free survival, p = 0.003, n = 212

    Not recorded as a finding: this platform holds no node for the endpoint

    Higher lycopene intake was associated with longer cardiac event-free survival compared with lower lycopene intake (p = 0.003).

    PMID 23076979 · one of two readings recorded this

  • cardiac event-free survival, low vs high lycopene

    decreases, p = 0.027

    > 3 g/day HR = 3.01; p = 0.027

    PMID 23076979 · one of two readings recorded this

  • cardiac event-free survival

    increases, p = 0.003, n = 212

    Higher lycopene intake was associated with longer cardiac event-free survival compared with lower lycopene intake (p = 0.003)

    PMID 23076979 · one of two readings recorded this

  • DNA tail length by comet assay (lymphocyte DNA damage), pooled mean difference; LDL oxidation lag time also pooled

    decreases, MD -6.27 (95% CI -10.74, -1.90), p = 0.006

    Not recorded as a finding: this platform holds no node for the endpoint

    Our results indicate that lycopene supplementation significantly decreases the DNA tail length, as determined using comet assays, with a mean difference (MD) of -6.27 [95% confidence interval (CI) -10.74, -1.90] (P=.006) between the lycopene intervention groups and the control groups.

    PMID 23631493 · one of two readings recorded this

  • DNA tail length (comet assay)

    decreases, p = 0.006

    with a mean difference (MD) of -6.27 [95% confidence interval (CI) -10.74, -1.90] (P=.006) between the lycopene intervention groups and the control groups

    PMID 23631493 · one of two readings recorded this

  • low-density lipoprotein lag time

    no effect, p = 0.24

    Lycopene supplementation does not significantly prolong the lag time of low-density lipoprotein (MD 3.76 [95% CI -2.48, 10.01]; P=.24)

    PMID 23631493 · one of two readings recorded this

  • diastolic blood pressure change, individual trial

    unclear

    Paterson, 2006,, U.K, Europe | single-blind, RCT | L: carotenoid-rich canned soups C: carotenoid-poor canned soups | L: 4.5 C: 0 | 4 weeks | SBP: 1 vs. 2 DBP: 1 vs. 2 | healthy adult, 12 m/24 f, 43.5 ± 23.5 years | L: 36 C: 36 | included | by a three-day estimated diet diary

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.087

    the overall pooled estimate of lycopene on DBP was −3.809 mmHg (95% CI, −8.177, 0.560, p = 0.087)

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.097, n = 5

    All | 5 | −0.315 (−0.687, 0.057) | 0.097 | 0.555 | 0

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.108, n = 3

    <80 mmHg | 3 | −0.308 (−0.683, 0.068) | 0.108 | 0.927 | 0.0

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.086, n = 3

    >8 weeks | 3 | −0.328 (−0.703, 0.046) | 0.086 | 0.434 | 0.0

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.862, n = 2

    Asia | 2 | −0.408 (−5.003, 4.188) | 0.862 | 0.095 | 64.1

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.108, n = 3

    Other regions | 3 | −0.308 (−0.683, 0.068) | 0.108 | 0.927 | 0.0

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.111, n = 2

    <12 mg/day | 2 | −0.305 (−0.681, 0.071) | 0.111 | 0.750 | 0.0

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.159, n = 2

    No-support by funding | 2 | −1.956 (−4.674, 0.763) | 0.159 | 0.572 | 0

    PMID 24051501 · one of two readings recorded this

  • diastolic blood pressure, pooled net change

    no effect, p = 0.139, n = 3

    Support by funding | 3 | −0.284 (−0.659, 0.092) | 0.139 | 0.530 | 0

    PMID 24051501 · one of two readings recorded this

  • publication bias, DBP (Egger test)

    no effect, p = 0.751

    results of Funnel plots and Egger’s test of trials showed no publication bias (p = 0.192 and 0.751 for SBP and DBP, respectively)

    PMID 24051501 · one of two readings recorded this

  • publication bias, SBP (Egger test)

    no effect, p = 0.192

    results of Funnel plots and Egger’s test of trials showed no publication bias (p = 0.192 and 0.751 for SBP and DBP, respectively)

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure change, individual trial

    unclear

    Paterson, 2006,, U.K, Europe | single-blind, RCT | L: carotenoid-rich canned soups C: carotenoid-poor canned soups | L: 4.5 C: 0 | 4 weeks | SBP: 1 vs. 2 DBP: 1 vs. 2 | healthy adult, 12 m/24 f, 43.5 ± 23.5 years | L: 36 C: 36 | included | by a three-day estimated diet diary

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure change, individual trial

    unclear

    Kim, 2011, Yonsei, Asia | double-blind, RCT | L: tomato extract capsule (Lyc-O-Mato) C: placebo capsule | L1: 6 L2: 15 C: 0 | 8 weeks | SBP: −3.2 vs. −0.6 | healthy male, smoker or alcohol-drinker, low intake of fruits and vegetables; male, 33.5–34.8 years | L1:41 L2: 37 C: 38 | negligible | by 24-h recall method and semi-quantitative food frequency questionnaire

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure (mmHg), pooled weighted mean difference of net change, lycopene supplement versus placebo or lycopene-free diet; diastolic blood pressure also pooled, over 40 words of prose in its only sentence

    pooled SBP WMD -4.953 mmHg (95% CI -8.820, -1.086), p = 0.012

    Not recorded as a finding: the direction is carried only as a signed number

    The overall pooled estimate of the lycopene treatment on SBP was −4.953 mmHg (95% CI, −8.820, −1.086, p = 0.012).

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    decreases, p = 0.012, n = 6

    The overall pooled estimate of the lycopene treatment on SBP was −4.953 mmHg (95% CI, −8.820, −1.086, p = 0.012)

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    decreases, p = 0.012, n = 6

    All | 6 | −4.953 (−8.820, −1.086) | 0.012 | 0.034 | 58.5

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    no effect, p = 0.467, n = 3

    <120 mmHg | 3 | −1.441 (−5.320, 2.439) | 0.467 | 0.731 | 0.0

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    no effect, p = 0.056, n = 4

    >8 weeks | 4 | −4.324 (−8.753, 0.105) | 0.056 | 0.100 | 52.1

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    decreases, p = 0.002, n = 3

    Asia | 3 | −7.661 (−12.480, −2.842) | 0.002 | 0.069 | 62.7

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    no effect, p = 0.524, n = 3

    Other regions | 3 | −1.368 (−5.573, 2.838) | 0.524 | 0.723 | 0.0

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    no effect, p = 0.397, n = 2

    <12 mg/day | 2 | −1.953 (−6.473, 2.568) | 0.397 | 0.680 | 0.0

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    no effect, p = 0.174, n = 2

    No-support by funding | 2 | −5.363 (−13.095, 2.369) | 0.174 | 0.041 | 76.1

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled net change

    no effect, p = 0.1, n = 4

    Support by funding | 4 | −4.481 (−9.821, 0.859) | 0.100 | 0.061 | 59.3

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, pooled weighted mean difference (mmHg) of lycopene supplement versus control across six trial data sets; acquisition protocol not stated

    WMD -4.953 mmHg (95% CI, -8.820, -1.086, p = 0.012), p = 0.012

    Not recorded as a finding: the direction is carried only as a signed number

    The overall pooled estimate of the lycopene treatment on SBP was −4.953 mmHg (95% CI, −8.820, −1.086, p = 0.012).

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, sensitivity analysis (fixed-effect), highest estimate

    decreases

    while analysis using fixed-effect model showed that no trials had substantial influence on the pooled analysis, and the results ranged from −4.128 (95% CI: −7.024, −1.233) to −5.738 (95% CI: −9.945, −1.530) mmHg

    PMID 24051501 · one of two readings recorded this

  • systolic blood pressure, sensitivity analysis (fixed-effect), lowest estimate

    decreases

    while analysis using fixed-effect model showed that no trials had substantial influence on the pooled analysis, and the results ranged from −4.128 (95% CI: −7.024, −1.233) to −5.738 (95% CI: −9.945, −1.530) mmHg

    PMID 24051501 · one of two readings recorded this

  • correlation between serum and dietary lycopene

    no effect

    No correlation between serum and dietary lycopene was detected

    PMID 24180552 · one of two readings recorded this

  • correlation of serum lycopene with prior nutritional supplement use

    decreases

    A significant positive correlation between serum lycopene, weight, and body mass index, and a negative correlation between serum lycopene and piror nutritional supplement use was detected

    PMID 24180552 · one of two readings recorded this

  • correlation of serum lycopene with weight and body mass index

    increases

    A significant positive correlation between serum lycopene, weight, and body mass index, and a negative correlation between serum lycopene and piror nutritional supplement use was detected

    PMID 24180552 · one of two readings recorded this

  • gastrointestinal tolerance of tomato juice

    no effect

    TJ was well tolerated without any gastrointestinal side effects

    PMID 24180552 · one of two readings recorded this

  • serum lycopene change from baseline to endpoint

    increases

    increased serum lycopene levels were observed in the 8 and 12 oz groups from baseline to endpoint

    PMID 24180552 · one of two readings recorded this

  • serum lycopene concentration by liquid chromatography-mass spectrometry after daily tomato juice (4, 8 or 12 oz)

    increases, increased serum lycopene levels in the 8 and 12 oz groups from baseline to endpoint

    Not recorded as a finding: this platform holds no node for the endpoint

    TJ was well tolerated without any gastrointestinal side effects, and increased serum lycopene levels were observed in the 8 and 12 oz groups from baseline to endpoint.

    PMID 24180552 · one of two readings recorded this

  • serum lycopene concentration, liquid chromatography-mass spectrometry, after daily tomato juice during radiotherapy

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    TJ was well tolerated without any gastrointestinal side effects, and increased serum lycopene levels were observed in the 8 and 12 oz groups from baseline to endpoint.

    PMID 24180552 · one of two readings recorded this

  • weight change

    no effect

    Despite no reported change in dietary intake, non-significant weight loss was observed in the control group but not the intervention group participants

    PMID 24180552 · one of two readings recorded this

  • lethal prostate cancer, top versus bottom quintile of dietary lycopene, Cox HR

    decreases, HR 0.72; 95% CI 0.56 to 0.94

    Not recorded as a finding: no node for lethal prostate cancer; the incidence node covers total diagnoses only

    Higher lycopene intake was inversely associated with total prostate cancer and more strongly with lethal prostate cancer (top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04).

    PMID 24463248 · one of two readings recorded this

  • lethal prostate cancer, top vs bottom quintile of lycopene intake

    decreases, p = 0.04

    Not recorded as a finding: no outcome node for lethal prostate cancer

    Higher lycopene intake was inversely associated with total prostate cancer and more strongly with lethal prostate cancer (top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04).

    PMID 24463248 · one of two readings recorded this

  • lethal prostate cancer

    decreases, p = 0.04

    top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04

    PMID 24463248 · one of two readings recorded this

  • lethal prostate cancer

    decreases, p = 0.009

    for lethal prostate cancer: HR = 0.47; 95% CI = 0.29 to 0.75; P trend = .009

    PMID 24463248 · one of two readings recorded this

  • C-reactive protein change

    no effect

    C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04)

    PMID 24651682 · one of two readings recorded this

  • C-reactive protein change

    decreases, p = 0.04

    C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04)

    PMID 24651682 · one of two readings recorded this

  • C-reactive protein, postintervention

    The postintervention CRP level for women was 4.5 ± 3.6 mg/dL and for men was 2.4 ± 2.1 mg/dL

    PMID 24651682 · one of two readings recorded this

  • C-reactive protein, postintervention

    The postintervention CRP level for women was 4.5 ± 3.6 mg/dL and for men was 2.4 ± 2.1 mg/dL

    PMID 24651682 · one of two readings recorded this

  • C-reactive protein, preintervention

    The preintervention CRP level for women was 5.9 ± 3.7 mg/dL and for men was 2.2 ± 2.1 mg/dL

    PMID 24651682 · one of two readings recorded this

  • C-reactive protein, preintervention

    The preintervention CRP level for women was 5.9 ± 3.7 mg/dL and for men was 2.2 ± 2.1 mg/dL

    PMID 24651682 · one of two readings recorded this

  • plasma lycopene

    increases, p = 0.002

    Plasma lycopene levels increased in the intervention group compared with the usual care group (0.51 μmol/L to 0.76 μmol/L, P = .002; 0.56 μmol/L to 0.58 μmol/L)

    PMID 24651682 · one of two readings recorded this

  • plasma lycopene

    no effect

    Plasma lycopene levels increased in the intervention group compared with the usual care group (0.51 μmol/L to 0.76 μmol/L, P = .002; 0.56 μmol/L to 0.58 μmol/L)

    PMID 24651682 · one of two readings recorded this

  • serum C-reactive protein (CRP) in heart failure patients after 30 days of V8 vegetable juice providing 29.4 mg lycopene/day vs usual care

    decreases, CRP decreased in women but not in men, p = 0.04

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04).

    PMID 24651682 · one of two readings recorded this

  • serum C-reactive protein in heart failure patients after 30 days of V8 vegetable juice (29.4 mg lycopene/day) versus usual care

    decreases, decrease in women only, not in men, p = 0.04

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04).

    PMID 24651682 · one of two readings recorded this

  • mucinous ovarian cancer risk

    no effect, n = 3

    Histologically, the OR for serous ovarian cancer and mucinous ovarian cancer was 0.744 (95% CI, 0.545–1.016; n = 4) and 0.878 (95% CI, 0.554–1.393; n = 3), respectively

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk by dietary lycopene intake (food-frequency questionnaire), highest versus lowest category, pooled OR, postmenopausal-dominant women

    OR 0.963 (95% CI 0.859-1.080), not significant

    Not recorded as a finding: this platform holds no node for the endpoint

    Dietary lycopene consumption decreased the risk of ovarian cancer by 3.7% (OR, 0.963; 95% CI, 0.859–1.080), and no heterogeneity was observed across the studies (p = 0.336, I2 = 11.6%).

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk in postmenopausal women, pooled OR for highest versus lowest dietary lycopene intake

    OR 0.963 (95% CI 0.859-1.080), I2 = 11.6%; interval includes the null

    Not recorded as a finding: this platform holds no node for the endpoint

    Dietary lycopene consumption decreased the risk of ovarian cancer by 3.7% (OR, 0.963; 95% CI, 0.859–1.080), and no heterogeneity was observed across the studies (p = 0.336, I2 = 11.6%).

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk, sensitivity analysis highest pooled OR

    no effect

    No study had a substantial effect on the final risk estimate; the pooled OR varied from 0.938 to 0.981

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk, sensitivity analysis lowest pooled OR

    no effect

    No study had a substantial effect on the final risk estimate; the pooled OR varied from 0.938 to 0.981

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk

    no effect, p = 0.336, n = 10

    Dietary lycopene consumption decreased the risk of ovarian cancer by 3.7% (OR, 0.963; 95% CI, 0.859–1.080), and no heterogeneity was observed across the studies (p = 0.336, I2 = 11.6%)

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk

    no effect, n = 7

    The pooled OR for case-control studies and prospective studies was 0.981 (95% CI, 0.846–1.139; n = 7) and 0.871 (95% CI, 0.616–1.233; n = 3), respectively

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk

    no effect, n = 3

    omitting the studies with a recall duration of <1 year resulted in an OR of 0.973 (95% CI, 0.823–1.149; n = 3)

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk

    no effect, n = 3

    The pooled OR for case-control studies and prospective studies was 0.981 (95% CI, 0.846–1.139; n = 7) and 0.871 (95% CI, 0.616–1.233; n = 3), respectively

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk

    no effect, n = 7

    The final risk estimate for studies conducted in and outside of the US was 0.923 (95% CI, 0.770–1.106; n = 7) and 1.026 (95% CI, 0.849–1.240; n = 3), respectively

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk

    no effect, n = 3

    The final risk estimate for studies conducted in and outside of the US was 0.923 (95% CI, 0.770–1.106; n = 7) and 1.026 (95% CI, 0.849–1.240; n = 3), respectively

    PMID 24810584 · one of two readings recorded this

  • ovarian cancer risk

    no effect, n = 7

    Limiting the analysis to studies with higher response rates (>90%) resulted in an OR of 0.967 (95% CI, 0.849–1.102; n = 7)

    PMID 24810584 · one of two readings recorded this

  • publication bias (Begg test)

    no effect, p = 0.251

    Funnel plots (as displayed in Figure 2) with Begg's and Egger's tests did not support the existence of publication bias (Begg, p = 0.251; Egger, p = 0.406)

    PMID 24810584 · one of two readings recorded this

  • publication bias (Egger test)

    no effect, p = 0.406

    Funnel plots (as displayed in Figure 2) with Begg's and Egger's tests did not support the existence of publication bias (Begg, p = 0.251; Egger, p = 0.406)

    PMID 24810584 · one of two readings recorded this

  • serous ovarian cancer risk

    no effect, n = 4

    Histologically, the OR for serous ovarian cancer and mucinous ovarian cancer was 0.744 (95% CI, 0.545–1.016; n = 4) and 0.878 (95% CI, 0.554–1.393; n = 3), respectively

    PMID 24810584 · one of two readings recorded this

  • publication bias (Begg test)

    no effect, p = 0.293

    Testing publication bias using funnel plots and Egger's test did not produce statistically significant results (Begg, p = 0.293; Egger, p = 0.277)

    PMID 24848940 · one of two readings recorded this

  • publication bias (Egger test)

    no effect, p = 0.277

    Testing publication bias using funnel plots and Egger's test did not produce statistically significant results (Begg, p = 0.293; Egger, p = 0.277)

    PMID 24848940 · one of two readings recorded this

  • stroke risk (occurrence or mortality)

    decreases, p = 0.234, n = 7

    Specifically, lycopene decreased stroke risk by 19.3% (RR = 0.807, 95% CI = 0.680–0.957), and no heterogeneity was observed (p = 0.234, I2 = 25.5%)

    PMID 24848940 · one of two readings recorded this

  • stroke risk, sensitivity analysis omitting Hirvonen et al

    no effect

    In the sensitivity analyses, omitting the trial of Hirvonen et al resulted in an insignificant reduction in stroke risk (RR = 0.860, 95% CI = 0.704–1.051)

    PMID 24848940 · one of two readings recorded this

  • stroke risk, sensitivity range of pooled estimates (highest)

    decreases

    The resulting estimates varied from 0.754 (95% CI = 0.644–0.884) to 0.820 (95% CI = 0.701–0.958)

    PMID 24848940 · one of two readings recorded this

  • stroke risk, sensitivity range of pooled estimates (lowest)

    decreases

    The resulting estimates varied from 0.754 (95% CI = 0.644–0.884) to 0.820 (95% CI = 0.701–0.958)

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    decreases, n = 3

    Circulating lycopene effectively decreased stroke risk (RR = 0.693, 95% CI = 0.503–0.954, n = 3), but dietary lycopene did not show the same effect (RR = 0.862, 95% CI, 0.688–1.080, n = 4)

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    no effect, n = 4

    Circulating lycopene effectively decreased stroke risk (RR = 0.693, 95% CI = 0.503–0.954, n = 3), but dietary lycopene did not show the same effect (RR = 0.862, 95% CI, 0.688–1.080, n = 4)

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    decreases

    Stratifying the results by number of cases showed that excluding studies with fewer than 100 cases resulted in a significant difference (RR = 0.771, 95% CI = 0.654–0.909)

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    no effect

    Lycopene significantly decreased the risk of stroke among male subjects (RR = 0.738, 95% CI = 0.585–0.931; n = 4) but not significantly among females (RR = 0.910, 95% CI = 0.571–1.451) or combined subjects (RR = 0.931, 95% CI = 0.684–1.266)

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    no effect

    Lycopene significantly decreased the risk of stroke among male subjects (RR = 0.738, 95% CI = 0.585–0.931; n = 4) but not significantly among females (RR = 0.910, 95% CI = 0.571–1.451) or combined subjects (RR = 0.931, 95% CI = 0.684–1.266)

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    decreases, n = 4

    Lycopene significantly decreased the risk of stroke among male subjects (RR = 0.738, 95% CI = 0.585–0.931; n = 4) but not significantly among females (RR = 0.910, 95% CI = 0.571–1.451) or combined subjects (RR = 0.931, 95% CI = 0.684–1.266)

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    decreases, n = 2

    The pooled RR for stroke was 0.655 (95% CI = 0.491–0.874; n = 2) for studies conducted in Europe, and 0.917 (95% CI, 0.760–1.107; n = 5) outside of Europe

    PMID 24848940 · one of two readings recorded this

  • stroke risk

    no effect, n = 5

    The pooled RR for stroke was 0.655 (95% CI = 0.491–0.874; n = 2) for studies conducted in Europe, and 0.917 (95% CI, 0.760–1.107; n = 5) outside of Europe

    PMID 24848940 · one of two readings recorded this

  • baseline EDV, CVD patients vs healthy volunteers

    decreases, p = 0.008

    At baseline, CVD patients had impaired EDV compared with HV (30% lower; 95% CI: -45% to -10%, P = 0.008)

    PMID 24911964 · one of two readings recorded this

  • baseline LDL cholesterol, CVD patients vs healthy volunteers

    decreases, p = 0.001

    despite lower LDL cholesterol (1.2 mmol/L lower, 95% CI: -1.6 to -0.9 mmol/L, P<0.001)

    PMID 24911964 · one of two readings recorded this

  • blood pressure, arterial stiffness, lipids and hsCRP

    no effect

    Blood pressure, arterial stiffness, lipids and hsCRP levels were unchanged for lycopene vs. placebo treatment groups in the CVD arm as well as the HV arm

    PMID 24911964 · one of two readings recorded this

  • blood pressure, setting not stated

    no effect

    Not recorded as a finding: grouped with arterial stiffness and lipids in one sentence; blood pressure type and acquisition not stated, so no single node fits

    Blood pressure, arterial stiffness, lipids and hsCRP levels were unchanged for lycopene vs. placebo treatment groups in the CVD arm as well as the HV arm.

    PMID 24911964 · one of two readings recorded this

  • endothelium-dependent vasodilatation (EDV) forearm response to acetylcholine

    increases, p = 0.03

    EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo) without changes to EIDV, or basal NO responses

    PMID 24911964 · one of two readings recorded this

  • endothelium-dependent vasodilatation (EDV)

    no effect

    HVs did not show changes in EDV after lycopene treatment

    PMID 24911964 · one of two readings recorded this

  • endothelium-independent vasodilatation (EIDV) and basal NO responses

    no effect

    EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo) without changes to EIDV, or basal NO responses

    PMID 24911964 · one of two readings recorded this

  • forearm endothelium-dependent vasodilatation to intra-arterial acetylcholine, venous plethysmography

    increases, EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo), p = 0.03

    Not recorded as a finding: no_outcome_node: forearm blood-flow response is not flow-mediated dilation; no node for it

    EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo) without changes to EIDV, or basal NO responses.

    PMID 24911964 · both readings recorded this

  • post-therapy EDV in lycopene-treated CVD patients vs healthy volunteers at baseline

    no effect, p = 0.85

    Post-therapy EDV responses for lycopene-treated CVD patients were similar to HVs at baseline (2% lower, 95% CI: -30% to +30%, P = 0.85)

    PMID 24911964 · one of two readings recorded this

  • baseline-corrected 12 h AUC of total lycopene in the plasma triglyceride-rich lipoprotein fraction, HPLC-DAD-MS/MS, after 10 mg lycopene from tangerine versus red tomato juice

    increases, approximately 8.5 times more bioavailable from tangerine than red tomato juice

    Not recorded as a finding: the comparison was against another active treatment

    Lycopene from tangerine tomato juice was, on average, approximately 8.5 times more bioavailable compared to red tomato juice.

    PMID 25620547 · one of two readings recorded this

  • lycopene AUC in TRL, males vs females (tangerine juice)

    increases, p = 0.004, n = 11

    all males had higher AUC values for lycopene on tangerine tomatoes than all females, a statistically significant increase (P = 0.004)

    PMID 25620547 · one of two readings recorded this

  • lycopene AUC in TRL

    n = 11

    81.6 ± 32.1 nmol·hr/L TRL from red tomato juice, with significantly higher bioavailability from tangerine tomato juice (P<0.001)

    PMID 25620547 · one of two readings recorded this

  • lycopene AUC in TRL

    increases, n = 11

    total lycopene of 690.9 ± 117.8 nmol·hr/L TRL from tangerine tomato juice

    PMID 25620547 · one of two readings recorded this

  • lycopene bioavailability ratio, tangerine vs red tomato juice (AUC)

    increases, p = 0.001, n = 11

    lycopene from tangerine tomato juice was, on average, 8.5 times more bioavailable as compared lycopene from red tomato juice (P<0.001)

    PMID 25620547 · one of two readings recorded this

  • lycopene fractional absorption

    n = 11

    The average (± SEM) fractional absorption of this 10 mg dose was 47.70 ± 8.81% from tangerine tomato and 4.98 ± 1.92% from red tomato

    PMID 25620547 · one of two readings recorded this

  • lycopene fractional absorption

    n = 11

    The average (± SEM) fractional absorption of this 10 mg dose was 47.70 ± 8.81% from tangerine tomato and 4.98 ± 1.92% from red tomato

    PMID 25620547 · one of two readings recorded this

  • plasma triglyceride-rich lipoprotein lycopene AUC over 12 h (HPLC-DAD-MS/MS) after 10 mg lycopene from tangerine (94% cis) versus red (10% cis) tomato juice, and fractional absorption

    increases, lycopene approximately 8.5 times more bioavailable from tangerine than red tomato juice

    Not recorded as a finding: the comparison was against another active treatment

    Lycopene from tangerine tomato juice was, on average, approximately 8.5 times more bioavailable compared to red tomato juice.

    PMID 25620547 · one of two readings recorded this

  • within-subject ratio of lycopene AUC, tangerine/red

    increases, n = 11

    The mean AUC tangerine/AUCred (± SEM) was 52.5 ± 22.0

    PMID 25620547 · one of two readings recorded this

  • cis-lycopene isomer fraction, plasma

    plasma and prostate isomers were 47 and 80 % cis

    PMID 26202168 · one of two readings recorded this

  • cis-lycopene isomer fraction, prostate

    plasma and prostate isomers were 47 and 80 % cis

    PMID 26202168 · one of two readings recorded this

  • correlation of prostate lycopene with post-intervention plasma lycopene

    increases, p = 0.001

    Prostate lycopene concentration was moderately correlated with post-intervention plasma lycopene concentrations (r 0·60, P =0·001)

    PMID 26202168 · one of two readings recorded this

  • end-of-study prostate lycopene concentration, fold vs control

    increases, p = 0.001

    The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively

    PMID 26202168 · one of two readings recorded this

  • end-of-study prostate lycopene concentration, fold vs control

    increases, p = 0.001

    The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively

    PMID 26202168 · one of two readings recorded this

  • end-of-study prostate lycopene concentration, fold vs control

    no effect, p = 0.165

    The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively

    PMID 26202168 · one of two readings recorded this

  • end-of-study prostate lycopene concentration

    The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively

    PMID 26202168 · one of two readings recorded this

  • plasma lycopene concentration

    decreases

    the controls consuming the lycopene-restricted diet showed a decline in plasma lycopene concentration from 0·55 (sem 0·60) to 0·42 (sem 0·07) μmol/l ( - 24 %)

    PMID 26202168 · one of two readings recorded this

  • plasma lycopene concentration

    increases

    0·48 (sem 0·09) to 0·82 (sem 0·12) μmol/l (71 %)

    PMID 26202168 · one of two readings recorded this

  • plasma lycopene concentration

    increases

    from 0·68 (sem 0·1) to 1·13 (sem 0·09) μmol/l (66 %)

    PMID 26202168 · one of two readings recorded this

  • plasma lycopene concentration

    increases

    0·49 (sem 0·12) to 0·78 (sem 0·1) μmol/l (59 %)

    PMID 26202168 · one of two readings recorded this

  • Circulating lycopene dose-response, Begg's test for publication bias

    no effect, p = 0.35

    Begg's rank correlation test (P = 0.350) also indicated no publication bias

    PMID 26287411 · one of two readings recorded this

  • Circulating lycopene dose-response, Egger's test for publication bias

    p = 0.026

    Egger's linear regression test (P = 0.026) indicated publication bias existed

    PMID 26287411 · one of two readings recorded this

  • Dietary lycopene dose-response, Begg's test for publication bias

    no effect, p = 0.2

    Begg's rank correlation test (P = 0.200) and Egger's linear regression test (P = 0.220) indicated no publication bias

    PMID 26287411 · one of two readings recorded this

  • Dietary lycopene dose-response, Egger's test for publication bias

    no effect, p = 0.22

    Begg's rank correlation test (P = 0.200) and Egger's linear regression test (P = 0.220) indicated no publication bias

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    decreases

    0.95 96 (95% CI 0.93 to 0.99) for 10 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    no effect

    0.88 (95% CI 0.75 to 1.05) for 100 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    no effect

    0.89 (95% CI 0.74 to 1.08) for 110 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    decreases

    0.92 (95% CI 0.86 to 0.97) for 20 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    decreases

    0.88 (95% CI 0.80 to 0.96) for 30 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    decreases

    0.86 (95% CI 0.77 to 0.95) for 40 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    decreases

    0.85 (95% CI 0.76 to 0.94) for 60 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    decreases

    0.86 (95% CI 0.77 to 0.94) for 70 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    decreases

    0.87 (95% CI 0.76 to 0.99) for 80 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference

    no effect

    0.88 (95% CI 0.76 to 1.01) for 90 μg/dL

    PMID 26287411 · one of two readings recorded this

  • Prostate cancer risk at dietary lycopene dose vs 0.1 mg reference

    decreases

    0.95 (95% CI 0.90 to 0.99) for 12 mg

    PMID 26287411 · one of two readings recorded this

The whole record — 646 rows